论文部分内容阅读
作者把70例未经治疗的骨髓增生异常综合征(MDS)分为以13-顺维甲酸(13-CRA)治疗组与对照组。治疗组给予13-CRA 20mg/日,出现口渴、结膜刺激症状则减量至10mg/日直到停药。结果:非铁粒幼细胞性贫血(RA)患者死亡18/48例(治疗组7/30例,对照组11/18例);铁粒幼细胞性贫血(RAS)患者死亡3/22例(治疗组2/8例,对照组1/14例);RAS患者治疗组与对照组的生存期无差别:RA患者治疗组1年生存率为77%,对照组为36%(P=0.0041,差异显著)。治疗组与对照组的中性粒细胞数变化不大;治疗组血小板上升0.5×10~7/L,对照组下降1.7×10~9/L。维甲酸可能系通过抑制鸟
The authors categorized 70 untreated myelodysplastic syndromes (MDSs) into 13-cis-retinoic acid (13-CRA) -treated and control groups. The treatment group given 13-CRA 20mg / day, thirst, conjunctival irritation was reduced to 10mg / day until withdrawal. Results: 18/48 patients (77/30 in treatment group and 11/18 in control group) died of non-metalloarthropathic cell anemia (RA); 3/22 patients died of rachis cell anemia (RAS) 2/8 in the treatment group and 1/14 in the control group). There was no difference in the survival of the RAS patients between the treatment group and the control group. The 1-year survival rate was 77% in the RA group and 36% in the control group (P = 0.0041, Significant difference). The number of neutrophils in the treatment group and the control group changed little. The platelets in the treatment group increased by 0.5 × 10 ~ 7 / L and the control group decreased by 1.7 × 10 ~ 9 / L. Retinoids may be through the inhibition of birds